JPWO2021202767A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202767A5 JPWO2021202767A5 JP2022560318A JP2022560318A JPWO2021202767A5 JP WO2021202767 A5 JPWO2021202767 A5 JP WO2021202767A5 JP 2022560318 A JP2022560318 A JP 2022560318A JP 2022560318 A JP2022560318 A JP 2022560318A JP WO2021202767 A5 JPWO2021202767 A5 JP WO2021202767A5
- Authority
- JP
- Japan
- Prior art keywords
- oxygen
- formulation
- catalyst
- agent
- intestinal tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 238000009472 formulation Methods 0.000 claims 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 18
- 239000001301 oxygen Substances 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 239000003054 catalyst Substances 0.000 claims 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 13
- 239000012528 membrane Substances 0.000 claims 5
- 102000016938 Catalase Human genes 0.000 claims 4
- 108010053835 Catalase Proteins 0.000 claims 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 229940078916 carbamide peroxide Drugs 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 claims 3
- 229940045872 sodium percarbonate Drugs 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims 3
- 239000004343 Calcium peroxide Substances 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010022678 Intestinal infections Diseases 0.000 claims 2
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 claims 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 235000019402 calcium peroxide Nutrition 0.000 claims 2
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims 2
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 2
- 229960004995 magnesium peroxide Drugs 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 208000037384 Clostridium Infections Diseases 0.000 claims 1
- 241000186542 Clostridium baratii Species 0.000 claims 1
- 241000193155 Clostridium botulinum Species 0.000 claims 1
- 241000193171 Clostridium butyricum Species 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims 1
- 241000607626 Vibrio cholerae Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 102000038379 digestive enzymes Human genes 0.000 claims 1
- 108091007734 digestive enzymes Proteins 0.000 claims 1
- 210000004211 gastric acid Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 229940118696 vibrio cholerae Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005121P | 2020-04-03 | 2020-04-03 | |
| US63/005,121 | 2020-04-03 | ||
| PCT/US2021/025217 WO2021202767A1 (fr) | 2020-04-03 | 2021-03-31 | Thérapie d'aérobisation entérique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521322A JP2023521322A (ja) | 2023-05-24 |
| JPWO2021202767A5 true JPWO2021202767A5 (fr) | 2024-04-09 |
Family
ID=77922438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560318A Pending JP2023521322A (ja) | 2020-04-03 | 2021-03-31 | 腸酸素化治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US11883428B2 (fr) |
| EP (1) | EP4125847A4 (fr) |
| JP (1) | JP2023521322A (fr) |
| KR (1) | KR20220163450A (fr) |
| CN (1) | CN115666546A (fr) |
| CA (1) | CA3174395A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023521322A (ja) | 2020-04-03 | 2023-05-24 | ループオキシー・セラピューティクス・インコーポレイテッド | 腸酸素化治療 |
| CA3232378A1 (fr) * | 2021-09-29 | 2023-04-06 | Larry D. SUTTON | Therapie d'aerobisation enterique |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795316A (fr) | 1972-02-11 | 1973-05-29 | Nat Patent Dev Corp | Systeme catalytique presentant une activite enzymatique durable et de stabilite augmentee |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4851228A (en) | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
| DE3624506A1 (de) | 1986-07-19 | 1988-01-21 | Asanuma Camera Mechanical Lab | Verfahren zur farbtrennung beim farbfotografieren oder beim herstellen von abzuegen und trichromatisches trennfilter |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| TW403720B (en) | 1997-09-26 | 2000-09-01 | Mitsubishi Gas Chemical Co | Oxygen generating agent, carbon dioxide gas absorbent, the transport system and the transport method of living fish |
| JP2004531212A (ja) | 2000-10-27 | 2004-10-14 | ジェネンコア インターナショナル インコーポレーテッド | 固形粒子又は顆粒中の酸化安定剤としてのカタラーゼ |
| US6838093B2 (en) | 2001-06-01 | 2005-01-04 | Shire Laboratories, Inc. | System for osmotic delivery of pharmaceutically active agents |
| ES2282492T3 (es) * | 2001-11-30 | 2007-10-16 | Pfizer Products Inc. | Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno. |
| US20060134186A1 (en) * | 2002-03-28 | 2006-06-22 | Carlton Richard M | Oxygenating agents for enhancing host responses to microbial infections |
| US20070166373A1 (en) | 2006-01-14 | 2007-07-19 | Hasmukh Patel | Pre-fabricated semi-permeable capsule shells containing a semipermeable layer on a water-dispersible/soluble gelatinous shell for osmotic drug delivery system |
| US20080159987A1 (en) | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
| FR2936709B1 (fr) | 2008-10-02 | 2012-05-11 | Ethypharm Sa | Comprimes alcoolo-resistants. |
| BR112012021275B1 (pt) | 2010-02-23 | 2021-07-27 | Da Volterra | Formulação compreendendo um adsorvente misturado com carragenina, para entrega oral e liberação controlada de adsorventes no intestino, e, uso de uma formulação |
| US20110305738A1 (en) * | 2010-06-09 | 2011-12-15 | Ladizinsky Daniel A | Oxygenating Oral Compositions |
| AT512342B1 (de) | 2011-12-19 | 2013-10-15 | Sciotec Diagnostic Technologies Gmbh | Zusammensetzung |
| GB201400442D0 (en) | 2014-01-10 | 2014-02-26 | Sigmoid Pharma Ltd | Compositions for use in the treatment of ulcerative colitis |
| WO2015192136A1 (fr) | 2014-06-13 | 2015-12-17 | Liveleaf, Inc. | Agent non toxique pour traitement à large spectre, bactéricide ou bactériostatique, de bactéries résistantes aux antibiotiques chez les animaux |
| WO2016036938A2 (fr) * | 2014-09-03 | 2016-03-10 | Federle Michael C | Compositions effervescentes et leurs procédés de production |
| WO2016073562A1 (fr) | 2014-11-04 | 2016-05-12 | Synthetic Biologics, Inc. | Procédés et compositions pour l'inhibition de clostridium difficile |
| WO2016196440A1 (fr) | 2015-06-01 | 2016-12-08 | Xeno Biosciences Inc. | Procédés et compositions pour moduler le microbiote intestinal et gérer poids |
| JP5878669B1 (ja) | 2015-08-19 | 2016-03-08 | 三生医薬株式会社 | 腸溶性カプセル |
| JP2019510805A (ja) * | 2016-04-07 | 2019-04-18 | ユニバーシティ・カレッジ・ダブリン，ナショナル・ユニバーシティ・オブ・アイルランド，ダブリン | 炎症性腸疾患の治療 |
| WO2017189621A1 (fr) | 2016-04-26 | 2017-11-02 | Symbiotic Health Inc. | Macro-émulsion stable pour l'administration par voie orale de peptides, protéines et produits thérapeutiques cellulaires solubilisés |
| CA3045011A1 (fr) | 2016-11-30 | 2018-06-07 | Xeno Biosciences Inc. | Preparations pharmaceutiques et procedes de gestion du poids et de modulation du microbiote intestinal |
| WO2018132871A1 (fr) | 2017-01-17 | 2018-07-26 | Macquarie University | Procédé de production de produits chimiques dans une levure |
| BR112019018738A2 (pt) | 2017-03-10 | 2020-04-07 | Biohm Health Llc | composições e métodos para promoção de uma flora microbiana saudável em um mamífero |
| WO2019165338A1 (fr) * | 2018-02-23 | 2019-08-29 | Ladizinsky Daniel A | Compositions orales et topiques d'oxygénation |
| JP2023521322A (ja) | 2020-04-03 | 2023-05-24 | ループオキシー・セラピューティクス・インコーポレイテッド | 腸酸素化治療 |
| WO2021202767A1 (fr) | 2020-04-03 | 2021-10-07 | Lpoxy Therapeutics, Inc | Thérapie d'aérobisation entérique |
| GB2609445A (en) | 2021-07-30 | 2023-02-08 | Glasport Bio Ltd | Compositions and methods |
| CA3232378A1 (fr) | 2021-09-29 | 2023-04-06 | Larry D. SUTTON | Therapie d'aerobisation enterique |
-
2021
- 2021-03-31 JP JP2022560318A patent/JP2023521322A/ja active Pending
- 2021-03-31 KR KR1020227038460A patent/KR20220163450A/ko unknown
- 2021-03-31 EP EP21778762.1A patent/EP4125847A4/fr active Pending
- 2021-03-31 CN CN202180036431.1A patent/CN115666546A/zh active Pending
- 2021-03-31 CA CA3174395A patent/CA3174395A1/fr active Pending
- 2021-06-21 US US17/304,447 patent/US11883428B2/en active Active
-
2022
- 2022-02-04 US US17/650,055 patent/US11944641B2/en active Active
-
2023
- 2023-02-14 US US18/169,061 patent/US20230190794A1/en active Pending
- 2023-02-14 US US18/169,073 patent/US20230270777A1/en active Pending
- 2023-02-14 US US18/169,095 patent/US11975023B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faber et al. | The impact of intestinal inflammation on the nutritional environment of the gut microbiota | |
| JP3875262B2 (ja) | 殺菌剤としての酸性化したニトリット | |
| EP2338476B1 (fr) | Suppositoire pour administration rectale, vaginale ou urétrale contenant un probiotique, un antibiotique et un acide gras insaturé non-estérifié | |
| ES2676168T3 (es) | Procedimientos para tratar enfermedades gastrointestinales | |
| US11975023B2 (en) | Methods for inhibiting anaerobic microorganisms | |
| JP2008540507A (ja) | 抗菌剤およびカルベオール、チモール、オイゲノール、ボルネオールならびにカルバクロールから選択される活性成分を含んでなる医薬組成物 | |
| CN103108643A (zh) | 包含过氧化物、醇和螯合剂的抗菌剂 | |
| US20230277497A1 (en) | Enteric aerobization therapy | |
| JP2013075927A (ja) | バイオフィルム形成抑制剤 | |
| Manson et al. | Selective intestinal decontamination for prevention of wound colonization in severely burned patients: a retrospective analysis | |
| KR20230096025A (ko) | 미생물 병원체를 억제하기 위한 비타민의 직접 전달 | |
| HU219234B (en) | Lantionin containing oral pharmaceutical compositions for the treatment of disorders of the gastrointestinal system caused by bacteria | |
| JPWO2021202767A5 (fr) | ||
| JPH0656679A (ja) | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 | |
| WO2021202767A1 (fr) | Thérapie d'aérobisation entérique | |
| FINEGOLD | Intestinal microbial changes and disease as a result of antimicrobial use | |
| FR2966732A1 (fr) | Utilisation de l'acide cinnamique pour prevenir ou traiter des infections provoquees par un antigene resistant ou une combinaison d'antigenes | |
| CA2669871A1 (fr) | Composition terpenique anti-microorganisme | |
| RU2053773C1 (ru) | Способ подавления микрофлоры | |
| JPH06145066A (ja) | 化学療法剤の作用増強並びに感染症予防及び治療用の医薬組 成物 | |
| KR20180011824A (ko) | 소화장관 전달효율이 증진된 경구투여용 가축용 생균제 타블렛 및 그 제조방법 |